Inactive Instrument

All News Arcturus Therapeutics Ltd Nasdaq

Equities

IL0011280240

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024	Apr. 25	BU
Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing	Mar. 27	MT
Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	Mar. 21	MT
Arcturus Therapeutics : Positive Results of Phase III Study of Bivalent Version of Kostaive®, Self-Amplifying mRNA Vaccine Against COVID-19 (Ancestral Strain and Omicron BA.4/5), for Booster Vaccination Conducted in Japan - Form 8-K	Mar. 19	PU
Transcript : Arcturus Therapeutics Holdings Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:45 AM	Mar. 14
Canaccord Genuity Adjusts Arcturus Therapeutics Holdings' PT to $87 From $81, Maintains Buy Rating	Mar. 11	MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $58 From $45, Maintains Overweight Rating	Mar. 08	MT
Transcript : Arcturus Therapeutics Holdings Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Arcturus Therapeutics Swings to Q4 Net Loss, Revenue Drops	Mar. 07	MT
Arcturus Therapeutics: Q4 Earnings Snapshot	Mar. 07	AQ
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q4 Revenue $34M, vs. Street Est of $37.9M	Mar. 07	MT
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 07	CI
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress	Mar. 07	BU
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference	Feb. 26	BU
Arcturus Therapeutics Holdings Inc. Announces Executive Changes	Feb. 23	CI
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission, for ARCT-032, for the Treatment of Cystic Fibrosis	Feb. 23	AQ
Arcturus Gets European Orphan Medicinal Product Label For ARCT-032 to Treat Cystic Fibrosis	Feb. 22	MT
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis	Feb. 22	BU
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024	Feb. 20	BU
Citigroup Raises Price Target on Arcturus Therapeutics to $48 From $40, Maintains Buy Rating	Feb. 08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Arcturus Therapeutics Ltd Nasdaq

Equities

IL0011280240

All News

Filters